DAPA MET XR 5MG+1000MG TABLET

DAPA MET XR 5MG+1000MG TABLET is a combination medication that contains two active ingredients: Dapagliflozin & Metformin. It is prescribed for the management of type 2 diabetes mellitus to help control blood sugar levels. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and Metformin is a biguanide antidiabetic drug. Together, they work to improve glycemic control in individuals with type 2 diabetes.

Uses:

DAPA MET XR 5mg + 1000mg Tablet is used for the following purposes:

1. Type 2 Diabetes: It is prescribed to adults with type 2 diabetes mellitus to help lower blood sugar levels. The combination of Dapagliflozin and Metformin works in different ways to reduce glucose levels, promoting better glycemic control.

Side Effects:

DAPA MET XR 5mg + 1000mg Tablet may cause side effects in some individuals. Common side effects of this medication may include:

1. Urinary Tract Infections: Dapagliflozin may increase the risk of urinary tract infections in some individuals.
2. Genital Yeast Infections: Some users of Dapagliflozin may experience genital yeast infections, especially in women.
3. Increased Urination: Dapagliflozin can lead to increased urination due to its mechanism of action in the kidneys.
4. Stomach Upset: Metformin may cause gastrointestinal discomfort, such as nausea, vomiting, or diarrhea, especially during the initial stages of treatment.
5. Lactic Acidosis: Although rare, Metformin may lead to a serious condition called lactic acidosis, especially in individuals with kidney or liver impairment.

It is essential to report any severe or persistent side effects to a healthcare professional promptly.

When Not to Use:

DAPA MET XR 5mg + 1000mg Tablet should not be used under the following circumstances:

1. Type 1 Diabetes: This medication is specifically for type 2 diabetes and should not be used to treat type 1 diabetes.
2. Diabetic Ketoacidosis: DAPA MET XR is not suitable for the treatment of diabetic ketoacidosis, a life-threatening condition that requires immediate medical attention.
3. Severe Kidney or Liver Impairment: Individuals with severe kidney or liver problems may not be suitable candidates for DAPA MET XR, as it can increase the risk of lactic acidosis.
4. Allergy to the Components: If an individual has a known allergy or sensitivity to Dapagliflozin, Metformin, or any other components of the tablet, they should avoid using this medication.
5. Dehydration or Low Blood Volume: Dapagliflozin can exacerbate dehydration or low blood volume in some individuals.

Always follow the prescribed dosage and usage instructions provided by the healthcare professional. Inform your doctor about any medical conditions or medications you are taking to avoid potential interactions or contraindications. If you experience any adverse reactions while using DAPA MET XR 5mg + 1000mg Tablet, seek immediate medical attention. Regular monitoring and follow-up with a healthcare provider are essential for individuals taking this medication for diabetes management.